Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

68 Views

Physician

Resident

NewPractitioner

Session: ADVANCED MODALITIES. Cardiac Toxicity in Thoracic Radiation Oncology: Heart of the Matter or Doesn’t Matter?

3 - Don’t Go Breaking My Heart: Cardiac Toxicity Prevention, Management and Follow-Up through Multidisciplinary Care

Friday, March 15, 2024

8:00 AM - 9:00 AM ET

Location: Grand Ballroom VI-VIII

Speaker(s)

Arya Amini, MD

Associate Professor
City of Hope National Medical Center
Duarte, California, United States

Disclosure(s): AstraZeneca: Consultant (Ongoing); RefleXion: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Roche/Genentech: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Takeda Pharma: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Varian Medical Systems: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)

PDF Slides

Disclosure(s):

Arya Amini, MD: AstraZeneca: Consultant (Ongoing); RefleXion: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Roche/Genentech: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Takeda Pharma: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Varian Medical Systems: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)

Learning Objectives:

Upon completion, participants will understand general principles behind the mechanism of radiation induced cardiac toxicity.
Upon completion, participants will be more aware of how to risk stratify their patients based on cardiac comorbidities and risks from treatment.
Upon completion, participants will have a general understanding of the current guidelines in prevention and management of cardiac toxicity in patients undergoing cancer directed therapies.